21 February 2022
Consultation is now open on our guideline for the treatment of psoriatic arthritis (PsA) with biologics and targeted synthetic DMARDs.
The guideline offers systematic and evidence-based recommendations to support UK clinicians in the prescription of bDMARD and tsDMARD therapies in adult patients with PsA.
The guideline also includes information for those managing patients with extra-articular manifestations such as uveitis and inflammatory bowel disease (IBD), as well as those who smoke or are overweight.
The consultation period closes at 23:59 on Saturday 5 March 2022.
To submit comments, please email the below consultation form to guidelines@rheumatology.org.uk.
Draft guideline
Consultation form